BenevolentAI announces licensing agreement with Janssen
pharmafile | November 8, 2016 | News story | Research and Development | Janssen, Johnson & Johnson, artificial intelligence
BenevolentAI, a British artificial intelligence company, announced a licensing agreement to develop a select number of drug candidates with Janssen, of Johnson & Johnson. BenevolentAI will use their artificial intelligence technology, named the Judgement Augmented Cognition System, to provide their scientists with the tools to analyse vast amounts of scientific data.
The particular drug candidates that BenevolentAI will turn their artificial intelligence systems upon is not known, but as part of the agreement they will have the sole right to develop, manufacture and commercial the candidates in all indications and all territories.
Currently BenevolentBio, the company’s human health and bioscience arm, focuses upon the disease areas of inflammation, neurodegeneration, orphan diseases and rare cancers. It is thought the drug candidates are likely to fall within one of these particular brackets.
BenevolentAI plans to begin late Phase IIb clinical trials in mid-2017.
Jackie Hunter, board director of BenevolentAI and CEO of BenevolentAI Bio, commented of the announcement: “We are delighted to have acquired rights to these compounds under a license agreement from Janssen. The agreement adds further depth to our clinical and pre-clinical development pipeline and marks a very exciting time for the role of artificial intelligence to benefit scientific discovery and humanity. The compounds come with a wealth of clinical and biological data that enables BenevolentAI to have further insights into the biology of diseases. Securing these novel clinical drug candidates perfectly aligns with our strategy of developing first-in-class and best-in-class stratified medicines to help patients with high unmet needs.”
Ben Hargreaves
Related Content
Johnson & Johnson commits $2bn to new manufacturing facility in North Carolina, US
Johnson & Johnson has announced a $2bn investment in a new manufacturing facility in Holly …
Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and …
Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
Johnson & Johnson has submitted an application to the European Medicines Agency for an indication …
